A citation-based method for searching scientific literature

Elizabeth K Lee, Ursula A Matulonis. Expert Opin Emerg Drugs 2020
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The forefront of ovarian cancer therapy: update on PARP inhibitors.
M R Mirza, R L Coleman, A González-Martín, K N Moore, N Colombo, I Ray-Coquard, S Pignata. Ann Oncol 2020
33
50

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew R Clamp, Giovanni Scambia,[...]. Lancet Oncol 2020
11
50

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
50

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
968
50

Structural basis for allosteric PARP-1 retention on DNA breaks.
Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A Hancock, Jamin D Steffen, Ramya Billur, Zain M Hannan, Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt,[...]. Science 2020
53
50

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.
Barbara M Norquist, Mark F Brady, Maria I Harrell, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Robert A Burger, Krishnansu S Tewari,[...]. Clin Cancer Res 2018
77
50

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
R E Miller, A Leary, C L Scott, V Serra, C J Lord, D Bowtell, D K Chang, D W Garsed, J Jonkers, J A Ledermann,[...]. Ann Oncol 2020
21
50

PARP inhibitors in ovarian cancer.
J A Ledermann. Ann Oncol 2016
71
50

Safety and dose modification for patients receiving niraparib.
J S Berek, U A Matulonis, U Peen, P Ghatage, S Mahner, A Redondo, A Lesoin, N Colombo, I Vergote, O Rosengarten,[...]. Ann Oncol 2019
5
50

First-line PARP inhibition in ovarian cancer - standard of care for all?
Susana N Banerjee, Christopher J Lord. Nat Rev Clin Oncol 2020
10
50


Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
Joo Ern Ang, Charlie Gourley, C Bethan Powell, Hilda High, Ronnie Shapira-Frommer, Vincent Castonguay, Jacques De Greve, Tina Atkinson, Timothy A Yap, Shahneen Sandhu,[...]. Clin Cancer Res 2013
84
50

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
772
50

Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
Angelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, Val Gebski, Laurence Gladieff, Jonathan Ledermann, Richard Penson, Amit Oza, Jacob Korach, Tomasz Huzarski,[...]. Eur J Cancer 2020
1
100

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean,[...]. Lancet Oncol 2020
24
50

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
211
50

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
717
50

Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, Laura Arenare, Domenica Lorusso, Graziana Ronzino, Rossella Lauria, Gennaro Cormio, Claudia Carella, Paolo Scollo,[...]. Gynecol Oncol 2020
16
50

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
50

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
Kaiming Sun, Keith Mikule, Zebin Wang, Grace Poon, Aparajitha Vaidyanathan, Gillian Smith, Zhi-Yi Zhang, Jeffrey Hanke, Sridhar Ramaswamy, Jing Wang. Oncotarget 2018
40
50

Genetic and molecular changes in ovarian cancer.
Robert L Hollis, Charlie Gourley.  2016
45
50

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
269
50

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
673
50

Is postoperative computed tomography evaluation a prognostic indicator in patients with optimally debulked advanced ovarian cancer?
Domenica Lorusso, Italo Sarno, Violante Di Donato, Antonella Palazzo, Elena Torrisi, Laura Pala, Alfonso Marchiano, Francesco Raspagliesi. Oncology 2014
6
50

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Xuan Jiang, Xiaoying Li, Weihua Li, Huimin Bai, Zhenyu Zhang. J Cell Mol Med 2019
40
50

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
338
50

Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer.
C M Kurbacher, I A Cree, H W Bruckner, U Brenne, J A Kurbacher, K Müller, T Ackermann, T J Gilster, L M Wilhelm, H Engel,[...]. Anticancer Drugs 1998
94
50

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
612
50

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Christin Tse, Alexander R Shoemaker, Jessica Adickes, Mark G Anderson, Jun Chen, Sha Jin, Eric F Johnson, Kennan C Marsh, Michael J Mitten, Paul Nimmer,[...]. Cancer Res 2008
50

miR-7 Reverses Breast Cancer Resistance To Chemotherapy By Targeting MRP1 And BCL2.
Tianzi Hong, Jian Ding, Wenlian Li. Onco Targets Ther 2019
20
50

5-fluorouracil: mechanisms of action and clinical strategies.
Daniel B Longley, D Paul Harkin, Patrick G Johnston. Nat Rev Cancer 2003
50

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
801
50

Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.
Haiming Dai, Husheng Ding, X Wei Meng, Kevin L Peterson, Paula A Schneider, Judith E Karp, Scott H Kaufmann. Genes Dev 2015
30
50


Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.
Lin Chen, Simon N Willis, Andrew Wei, Brian J Smith, Jamie I Fletcher, Mark G Hinds, Peter M Colman, Catherine L Day, Jerry M Adams, David C S Huang. Mol Cell 2005
50


Induction of apoptosis by cancer chemotherapy.
S H Kaufmann, W C Earnshaw. Exp Cell Res 2000
900
50

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Triona Ni Chonghaile, Kristopher A Sarosiek, Thanh-Trang Vo, Jeremy A Ryan, Anupama Tammareddi, Victoria Del Gaizo Moore, Jing Deng, Kenneth C Anderson, Paul Richardson, Yu-Tzu Tai,[...]. Science 2011
369
50

Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate.
Lei Hu, Meng Chen, Xueran Chen, Chenggang Zhao, Zhiyou Fang, Hongzhi Wang, Haiming Dai. Cell Death Dis 2020
19
50

Mitochondrial apoptosis and BH3 mimetics.
Haiming Dai, X Wei Meng, Scott H Kaufmann. F1000Res 2016
22
50

A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines.
A L Blajeski, T J Kottke, S H Kaufmann. Exp Cell Res 2001
65
50

Evaluation of the BH3-only protein Puma as a direct Bak activator.
Haiming Dai, Yuan-Ping Pang, Marina Ramirez-Alvarado, Scott H Kaufmann. J Biol Chem 2014
42
50

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
Elisabet Wahlberg, Tobias Karlberg, Ekaterina Kouznetsova, Natalia Markova, Antonio Macchiarulo, Ann-Gerd Thorsell, Ewa Pol, Åsa Frostell, Torun Ekblad, Delal Öncü,[...]. Nat Biotechnol 2012
309
50

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
András Kotschy, Zoltán Szlavik, James Murray, James Davidson, Ana Leticia Maragno, Gaëtane Le Toumelin-Braizat, Maïa Chanrion, Gemma L Kelly, Jia-Nan Gong, Donia M Moujalled,[...]. Nature 2016
505
50

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
J D Leverson, H Zhang, J Chen, S K Tahir, D C Phillips, J Xue, P Nimmer, S Jin, M Smith, Y Xiao,[...]. Cell Death Dis 2015
296
50

Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity.
P Bouillet, D Metcalf, D C Huang, D M Tarlinton, T W Kay, F Köntgen, J M Adams, A Strasser. Science 1999
50

Ovarian cancer.
Ursula A Matulonis, Anil K Sood, Lesley Fallowfield, Brooke E Howitt, Jalid Sehouli, Beth Y Karlan. Nat Rev Dis Primers 2016
283
50

Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche.
Toshiro Sato, Robert G Vries, Hugo J Snippert, Marc van de Wetering, Nick Barker, Daniel E Stange, Johan H van Es, Arie Abo, Pekka Kujala, Peter J Peters,[...]. Nature 2009
50

FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.
Andrew Sunters, Silvia Fernández de Mattos, Marie Stahl, Jan J Brosens, Georgia Zoumpoulidou, Catherine A Saunders, Paul J Coffer, René H Medema, R Charles Coombes, Eric W-F Lam. J Biol Chem 2003
401
50

Reflections on My Life with Taxol.
Susan Band Horwitz. Cell 2019
2
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.